22–23 Jul 2026
Heidelberg Congress Center
Europe/Berlin timezone

A phase III, multi-state, randomised controlled trial evaluating the addition of exercise or compression therapy to best-practice usual breast cancer care to prevent breast cancer-related lymphoedema: The ACHIEVE trial protocol

22 Jul 2026, 12:00
1h 15m
Heidelberg Congress Center ( Heidelberg Congress Center )

Heidelberg Congress Center

Heidelberg Congress Center

Czernyring 20 69115 Heidelberg Germany
1 - Scientific Poster Poster Session

Speaker

Ms Camila Sanchez Saez (School of Allied Health, Sport and Social Work Griffith University, Queensland, Australia)

Description

Introduction: Breast cancer-related lymphoedema (BCRL) is a prevalent condition associated with lifelong physical, psychological and social burden, and lower quality of life. The primary aim of this trial is to determine if adding exercise therapy or compression therapy to usual care can prevent BCRL. Secondary aims evaluate effects on patient-reported outcomes and the cost-effectiveness of preventive strategies.

Methods: This multi-state, phase III, single-blind, parallel-group (1:1:1), randomised controlled trial will recruit adults with a first diagnosis of breast cancer who are at high risk of BCRL. Participants will be randomised to usual care, usual care plus exercise therapy, usual care plus compression therapy. 660 participants are needed to detect a 10% absolute difference in 12-month BCRL incidence between groups (α=0.05, β=0.2, 10% drop-out). BCRL incidence will be assessed using bioimpedance spectroscopy, circumferences, tissue dielectric constant and validated self-report measures, applying predetermined diagnostic thresholds. Secondary outcomes include patient-reported outcomes of symptoms, function, quality of life, mental health and physical activity as well as intervention cost-effectiveness. Usual care includes prospective surveillance (lymphoedema assessments of the upper-limb, postoperative lymphoedema education including risk reducing strategies and shoulder function rehabilitation). Exercise therapy (behaviour-change counselling and individualised prescription of aerobic and resistance training targeting 150 minutes per week) and compression therapy (provision of individually-fitted compression garments for daily wear) will be delivered through fortnightly calls over a 6-month period. Primary and secondary outcomes will be assessed at baseline, 3-, 6-, 12-, 24-months, and 5 years post-randomisation.

Results: Study ethics approval is under review. Study protocol will be registered on the Australian New Zealand Clinical Trial Registry (ANZCTR). Findings will be disseminated via peer-reviewed publications and national/international conferences.

Conclusion: This trial will determine the efficacy and cost-effectiveness of incorporating exercise therapy or compression therapy into best-practice usual breast cancer care for BCRL prevention.

Keywords

Breast Cancer-related Lymphoedema, Prevention, Exercise trial, Compression

Abstract submitters declaration yes
Conflict of Interest & Ethical Approval yes

Author

Ms Camila Sanchez Saez (School of Allied Health, Sport and Social Work Griffith University, Queensland, Australia)

Co-authors

Dr Amanda Pigott (Princess Alexandra Hospital, Queensland, Australia) Dr Boon Chua (University of New South Wales, New South Wales, Australia) Dr Camile Short (The University of Melbourne, Victoria, Australia) Dr Chris Pyke (Mater Private Hospital, The University of Queensland, Queensland, Australia) Dr Debbie Geyer (Lymphoedema Association Australia, Queensland, Australia) Dr Dimitrios Vagenas (Queensland University of Technology, Queensland, Australia) Dr Elizabeth Dylke (The University of Sydney, New South Wales, Australia) Frances Boyle (The University of Sydney, New South Wales, Australia) Ms Hildegard Reul-Hirche (School of Allied Health, Sport and Social Work Griffith University, Royal Brisbane and Women’s Hospital, Queensland, Australia) Dr Lara EdBrooke (Peter MacCallum Cancer Centre, The University of Melbourne, Victoria, Australia) Dr Leonie Young (Wesley Choices Program, Queensland, Australia) Prof. Louisa Collins (Cancer Council Queensland, Queensland, Australia) Prof. Louise Koelmeyer (Australian Lymphoedema Education, Research and Treatment Centre (ALERT), Macquarie University, New South Wales, Australia) Melanie Plinsinga (Australian Centre for Precision Health and Technology (PRECISE), Griffith University, Australia) Prof. Monika Janda (The University of Queensland, Queensland, Australia) Rosa Spence (Cancer Council Queensland) Sandi Hayes (Cancer Council Queensland, Queensland, Australia) Prof. Sandie McCarthy (Health Group, Griffith University, Queensland, Australia)

Presentation materials

There are no materials yet.